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Background: DNA methylation (5-methylcytosine (5mC)) patterns are often altered in cancers. Ten-eleven
translocation (Tet) proteins oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and
5-carboxylcytosine (5caC). In addition to their presumptive specific biological roles, these oxidised forms of
5mC may serve as intermediates in demethylation process. According to several reports, 5hmC levels are
strongly decreased in cancers; however, the distribution of 5fC and 5caC in malignant tissue has not been
studied.
Findings: Here, we examine the levels of 5hmC and 5caC in 28 samples of normal breast tissue, 59 samples
of invasive human breast cancer and 74 samples of gliomas using immunochemistry. In agreement with
previous reports, we show that 71 % of normal breast samples exhibit strong 5hmC signal, compared with
only 18 % of breast cancer samples with equivalent levels of 5hmC staining. Unexpectedly, although 5caC
is not detectable in normal breast tissue, 27 % of breast cancer samples exhibit significant staining for this
modification (p < 0.001). Surprisingly, the presence of immunochemically detectable 5caC is not associated
with the intensity of 5hmC signal in breast cancer tissue. In gliomas, we show that 5caC is detectable in
45 % of tumours.
Conclusions: We demonstrate that, unlike 5hmC, the levels of 5caC are elevated in a proportion of breast
cancers and gliomas. Our results reveal another level of complexity to the cancer epigenome, suggesting that
active demethylation and/or 5caC-dependent transcriptional regulation are pre-activated in some tumours and
may contribute to their pathogenesis. Larger studies to evaluate the clinicopathological significance of 5caC in
cancers are warranted.
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Background
DNA methylation (5-methylcytosine (5mC)) is an epi-
genetic modification, which contributes to the regulation
of gene expression in a wide range of biological contexts
[1]. The patterns of DNA methylation are altered in a
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otherwise stated.promoters of tumour-suppressor genes has been identi-
fied as one of the causes of cancer progression [3].
Ten-eleven translocation (Tet) proteins (Tet1/2/3)
contain a C-terminal catalytic dioxygenase domain that
oxidises 5mC to 5-hydroxymethylcytosine (5hmC) and
further to 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC) [4–6]. A number of recent studies suggest that
5hmC plays a specific role in both transcriptional regula-
tion and DNA demethylation in different biological
settings [7, 8]. Importantly, 5hmC is strongly depleted in
human cancers [9, 10] and its loss is accompanied with
malignant cellular transformation [11, 12].
5hmC has recently attracted considerable attention
from cancer biologists; however, the distribution of therticle is distributed under the terms of the Creative Commons Attribution
es/by/4.0/), which permits unrestricted use, distribution, and reproduction
is properly credited. The Creative Commons Public Domain Dedication
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nant tissue has not been studied. Nevertheless, both these
marks can be recognised and excised from DNA by
thymine-DNA glycosylase (TDG) followed by regeneration
of non-modified cytosine via base-excision repair (BER)
pathway leading to active Tet/TDG-dependent demethyla-
tion of certain genomic regions [5, 6, 13]. Since demethyla-
tion of promoters of tumour-suppressor genes has been
implicated in tumorigenesis [3], elucidating potential roles
of these modifications in cancers would be important for
understanding the mechanisms of cancer progression.
We previously showed that although both 5fC and
5caC are immunochemically detectable in mammalian
post-implantation embryos with similar patterns of
spatial distribution, the intensity of 5fC signal is always
considerably weaker than that of 5caC likely due to a
lower sensitivity of the 5fC antibody [14]. Thus, in this
study, we focused our analysis on 5caC aiming to deter-
mine the global levels of this mark in human breast
cancers and gliomas.
Methods
Patients and tissue samples
Paraffin-embedded formaldehyde-fixed tissue microarray
blocks were used for 5hmC and 5caC immunochemical
detection in breast cancers. The microarray blocks con-
tained 97 cores with 59 samples of invasive breast cancer
tissues with the rest of the cores representing normal
breast tissue. The breast cancer tissue samples were in-
vasive ductal carcinomas from patients who underwent
surgery for early stage breast cancers. All tumours were
reviewed by expert pathologist at the Nottingham
University Hospitals. All tumours were derived from
Caucasian patients diagnosed with breast cancer lacking
any known germ-line mutations in BRCA1 or BRCA2.
The ‘normal’ samples were tumour-associated normal
breast tissue removed at the time of definite surgery in
the Caucasian patients diagnosed with breast cancer
lacking any known germ-line mutations in BRCA1 or
BRCA2. Ethical approval for the breast cancer study was
granted by the Nottingham Research Ethics Committee
2 under the title ‘Development of a molecular genetic
classification of breast cancer’ (C202313). Examination
of 5caC distribution in gliomas was performed using
76 paraffin-embedded tumour sections from patients
treated at Nottingham University Hospitals between the
years 2005 and 2011. Of the glioma patients, 45/74
(60.8 %) were male. The median age of patients at inclu-
sion in the study was 47 years (range 22–81 years).
Twenty-seven percent (20/74) of the patients were diag-
nosed with a low grade glioma (all grade 2). Of the 54
high grade gliomas included in the study, 15/54 (27.8 %)
were grade 3 tumours and 39/54 (72.2 %) were grade 4
tumours. In patients with low grade glioma, 12/20(60.0 %) were male and the median age at inclusion in
the study was 33.5 years (range 25–57 years). The median
age at study inclusion was 54.5 years (range 22–81 years),
and 33/54 (61.1 %) patients with high grade glioma were
male. All the samples have been examined by an expert
neuropathologist. All the patients were referred from
Nottingham, Leicester, Lincoln and Derby, Leicestershire,
Northamptonshire and Rutland Research Ethics committee.
This study has been approved by the Regional Ethics
Committee (reference number 08/H0406/102). Biomax
US tissue microarray (BN1002a) was used for fluorescent
immunochemistry of normal breast tissue.
Immunohistochemistry, microscopy, scoring and statistical
analysis
3,3′-Diaminobenzidine (DAB)-based immunohistochemistry
was performed using the Novolink kit polymer detection
system (Cat. no.RE7280-K, Leica) following the manu-
facturer’s instructions. The slides were de-waxed and re-
hydrated according to the standard procedures and
incubated in the antigen retrieval citrate solution heated
to close to boiling for 20 min. Anti-5hmC (cat. no.
39791; Active Motif, 1:2000 dilution) and anti-5caC
(cat. no. 61225; Active Motif, 1:1000 dilution) rabbit
polyclonal antibodies were diluted in Leica diluent (cat.
no. AR9352) and incubated with the slides for 1 h at
room temperature. After incubation with primary
antibodies, the slides were washed in TBS and
incubated in post primary block solution for 30 min,
followed by washes in TBS and incubation with the
polymer solution for 5 min. The signal was visualised by
incubation of the slides in 1:20 diluted DAB solution for
5 min. Haematoxylin was used for nuclei visualisation.
5hmC signal was evaluated as undetectable (0), weak
(1), moderate (2) or strong (3). 5caC staining intensity
was assessed as negative (0) or positive (1). Paraffin-
embedded formaldehyde-fixed 12.5 dpc murine embry-
onic tissue was used as a positive control for 5hmC/
5caC immunostaining. Images were obtained using a
Nikon eclipse 80i microscope. Immunofluorescence
immunohistochemistry and confocal microscopy was
performed as described in [14]. Control staining without
primary antibody produced no detectable signal. Statis-
tical significance of the differences between the distribu-
tions of 5hmC and 5caC was determined by the ANOVA
single factor test. Chi-squared tests were used to examine
associations between two categorical variables.
Results
We have previously extensively used fluorescent immu-
nohistochemistry for detection of both 5hmC and 5caC
in mammalian and amphibian tissues [14–16]. Moreover,
our protocol for immunochemical detection of 5caC was
validated by mass spectrometric identification of the
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and fluorescence-based protocols for 5hmC/5caC immu-
nostaining, we initially performed detection of 5hmC
and 5caC in mouse embryonic and adult brain tissues
using the two immunostaining techniques (Fig. 1a–e). In
agreement with our previous results [14], 5caC was de-
tectable in 12.5 days post coitum (dpc) but not in the
adult mouse brain by both methods (Fig. 1a–c). Further-
more, whereas 5hmC staining was fairly uniform in 12.5
dpc mouse brain, both DAB-based and fluorescent
immunochemistry produced identical characteristic pat-
terns of 5caC distribution in embryonic brain tissue,
with staining intensity varying in the cells differentiating
towards different lineages [15] (Fig. 1a, c–d). In addition,
we obtained identical results from 5hmC and 5caC im-
munostaining of normal human breast tissue using both
versions of immunochemistry. Thus, whereas 5hmC
staining of these samples was relatively high, 5caC was12.5 dpc mouse brain
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the generation of 2.5XD signal intensity plots presented in (c). Merged view
channels in (e). Scale bar is 10 μm. e DAB-based detection of 5hmC in 12.5immunochemically undetectable in breast tissue samples
(Fig. 2a, b).
Since we obtained identical results using both staining
techniques, we decided to employ DAB-based immuno-
chemistry for 5hmC/5caC detection in breast cancers.
Initially, we examined the levels of 5caC in 59 samples
of invasive human breast cancers and 28 samples of nor-
mal breast tissue. Although we could not detect any
5caC staining in normal breast tissue samples, a signifi-
cant number of cancer samples (28 %, p < 0.001) exhib-
ited evident 5caC signal (Figs. 2c, d). In contrast, and in
agreement with previous studies [9, 10], 71 % of normal
breast samples exhibited strong 5hmC signal, whereas
only 18 % of breast cancer samples had comparable
levels of 5hmC staining. Thus, 5hmC staining was very
weak in 36 % and significantly decreased in 46 % of can-
cer samples (Fig. 2e, f ). Surprisingly, the presence of im-
munochemically detectable 5caC was not associatedC + 5caC
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Fig. 2 5caC levels are elevated in a range of human breast cancers. a Fluorescent 5caC and 5hmC immunostaining in normal breast tissue.
Individual channels and merged view are shown. b DAB-based 5caC and 5hmC immunostaining in normal breast tissue. c Examples of breast
cancer tissue with different levels of 5caC signal (designated as detectable or undetectable) used for the categorization of 5caC staining presented
in (d). d Proportions of breast cancers and samples of normal breast tissue with detectable 5caC staining. e Examples of breast cancer tissue with
different levels of 5hmC signal (designated as strong, moderate or weak) used for the categorization of 5hmC staining presented in (f). 5hmC
staining in 12.5 dpc embryonic brain is shown as a positive control. f Proportions of breast tumours, 5caC positive breast tumours and samples of
normal breast tissue exhibiting different levels of 5hmC staining. **p < 0.001
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sponding samples of malignant breast tissue (Fig. 2f ).
To extend our study with another type of cancer, we
performed immunochemical detection of 5caC in 74
samples of glioma tissue. Analogous to breast cancers,
this modification was detectable in 40 % of low and
46.3 % of high grade gliomas (Fig. 3a, b). Notably, the
presence of 5caC was not associated with glioma grade
(Fig. 3b).
Discussion
In one of the first studies reporting decreased levels of
5hmC in malignant tissue, it has been noted that the de-
pleted 5hmC content did not correlate with the levels of
Tet1/2/3 expression in a number of tumours [10]. Cor-
respondingly, here, we show that the levels of 5caC are
elevated in a considerable fraction of breast cancers we
analysed, including the tumour samples producing low
intensity of 5hmC staining. This suggests that, at least in
some cancers, depleted 5hmC may not necessarily indi-
cate low degrees of Tet-dependent 5mC oxidation. In
contrast, it is likely that Tet1/2/3 proteins are pre-
activated in certain cancer-related settings leading to the
preferential oxidation of 5mC to 5fC/5caC instead ofGlioma tissue
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5caC
A
Fig. 3 5caC immunostaining in human gliomas. a Examples of glioma tissu
detectable or undetectable) used for the categorization of 5caC staining pr
immunochemically detectable levels of 5caC5hmC. In this context, the presence of high 5caC levels
in cancer tissue may point at intensified ratios of active
demethylation or, alternatively, at repression of compo-
nents of BER machinery implicated into removal of this
mark from DNA [5, 6, 13]. Thus, both active remodel-
ling of DNA methylation patterns and 5caC-dependent
transcriptional regulation may participate in aberrant
nuclear reprogramming associated with pathogenesis of
cancers [2] adding another layer of complexity to the
epigenetic landscape of this disease.
Since the large body of experimental evidence have
previously indicated that 5hmC content is decreased in
cancers [9–12], it has been counterintuitive to search for
more oxidised forms of 5mC such as 5fC/5caC in
cancer-related contexts. With an exception of a recent
report, which did not find any significant difference in
5caC content between the cancer patient-derived and
healthy control blood samples [17], no attempt has been
made to systematically assess the global 5caC levels in
tumour tissue to date. Therefore, our observation that
5caC and, potentially, DNA demethylation, is elevated in
some tumours represents an important beginning for
deciphering the roles of this mark in carcinogenesis and
opens an avenue for further 5fC/5caC-related studies in60 53.7
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Eleftheriou et al. Clinical Epigenetics  (2015) 7:88 Page 6 of 6cancer systems. Future investigations on genomic distri-
butions of 5fC/5caC in tumour-derived cell lines and
larger studies on different types of cancers are necessary
to evaluate the functions and clinicopathological signifi-
cance of immunochemically detectable 5caC in tumour
tissue.
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